Clinical Trials in Tianjing, China
6 recruiting
Showing 1–6 of 6 trials
Recruiting
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
Limited Stage Small Cell Lung Cancer
AstraZeneca200 enrolled26 locationsNCT07161388
Recruiting
Not Applicable
Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
AML (Acute Myelogenous Leukemia)ALL (Acute B-Lymphoblastic Leukemia)MDS (Myelodysplastic Syndrome)
Institute of Hematology & Blood Diseases Hospital, China36 enrolled1 locationNCT07297576
Recruiting
Phase 3
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.240 enrolled28 locationsNCT06464991
Recruiting
Not Applicable
Efficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder
Shanghai Mental Health Center60 enrolled10 locationsNCT07031544
Recruiting
Phase 2
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Advanced Endometrial Cancer
3D Medicines (Sichuan) Co., Ltd.108 enrolled19 locationsNCT05112991
Recruiting
Phase 1
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Advanced Solid TumorsRefractory LymphomaRelapsed Hematologic Malignancy
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.111 enrolled8 locationsNCT06615193